Interstitial pneumonia is a common and major comorbidity affecting the prognosis of patients with systemic sclerosis (SSc). However, there are few reported cases of SSc-rheumatoid arthritis (RA) overlap-associated interstitial pneumonia. We herein report a case in which the clinical behavior and histopathology of interstitial pneumonia with SSc-RA overlap syndrome was followed over a long clini...

Although the relationship between malignancy risk with systemic sclerosis (SSc) has been inconclusive, there are some previous studies for a positive correlation. Most patients with SSc have some degree of lung parenchymal involvement in the form of interstitial thickening and fibrosis. Interstitial lung disease is the most common pulmonary manifestation of SSc. Interstitial lung disease follow...

We discuss a case that demonstrates the difficulties in making a confident diagnosis of interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Atypical symptoms can be present, suggesting the diagnosis of an underlying connective tissue disease (CTD), but it can take several years before a definite diagnosis can be made because there are insufficient features to fulfill the p...

Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by cutaneous and visceral fibrosis and widespread vascular pathology. Raynaud’s phenomenon is one of the most common manifestations of SSc. It may lead to complications such as digital ulceration and infarction and its treatment remains elusive. We present the case of a female patient with severe digital ischemia ...

The autoimmune disease scleroderma (systemic sclerosis (SSc)) is characterized by extensive tissue fibrosis, causing significant morbidity. There is no therapy for the fibrosis observed in SSc; indeed, the underlying cause of the scarring observed in this disease is unknown. Transforming growth factor-beta (TGFbeta) has long been hypothesized to be a major contributor to pathological fibrotic d...

Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). In clinical trials PAH-SSc has been grouped with other forms, including idiopathic PAH. The primary endpoint for most pivotal studies was improvement in exercise capacity. However, composite clinical endpoints that better reflect long-term outcome may be more meaningful. We discuss potential endpoints a...

About 20% of patients with systemic sclerosis have symptoms another connective tissue disease (CTD). Interstitial lung (ILD) is one the most common organ manifestations in (SSc) as well viral illnesses, such COVID-19, and can lead not only to diffuse alveolar damage, but also trigger an exacerbation fibrosis among preexisting ILD. It associated substantial morbidity mortality. According World S...

BACKGROUND Thyroid function abnormalities and thyroid autoantibodies have been frequently described in patients with systemic autoimmune diseases as systemic sclerosis (SSc). Serum TSH levels are higher in SSc patients with more severe skin diseases and a worse modified Rodnan skin score. Asymptomatic esophageal involvement due to SSc has never been described as a cause of severe hypothyroidism...

OBJECTIVE The aim of this study was to examine the parenchymal and extracellular matrix remodeling process in two histologic patterns-nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP)-in cases of idiopathic and sclerosis/systemic sclerosis (SSc)-associated interstitial pneumonia. METHODS We examined 15 cases of idiopathic NSIP, 10 cases of idiopathic UIP, 5 case...

Abstract Purpose of Review Interstitial lung disease (ILD) is the leading cause mortality in systemic sclerosis, a rare autoimmune characterised by fibrosis and vasculopathy. The variety phenotypes SSc-ILD have inspired multiple studies aimed at identification biomarkers which can provide disease-specific information but due to complex pathogenesis SSc-ILD, it has been challenging validate such...